Early Detection Research Network

Hepatocellular carcinoma Early Detection Strategy study

HEDS
316
Feng, ZidingFred Hutchinson Cancer Research Center
Biomarkers that pass the test on the HCC Phase 2 Validation Set will be included in the Phase 3 study. These makers, along with DCP, will not be measured in real time, but will be assayed retrospectively in a blinded fashion either from samples collected from the entire prospective cohort or from a nested case-control sample embedded in the whole cohort.
No design specified.
Glycomics
G.I. and Other Associated Cancers Research Group
3

Part 1: The first part of this study is to conduct follow-up for patients that were enrolled in the EDRN Phase 2 Validation Study called DCP (13). For this part of the study, four groups are defined as follows: a)   Vanguard Controls are cirrhotic controls, from the Phase 2 trial that have not developed HCC and sign a new consent form for HEDS participation. These patients will be followed for a minimum of an additional 24 months and have biospecimens collected every 6 months. b)   Vanguard Interval Controls are cirrhotic controls, from the Phase 2 trial that have not developed HCC and do not sign a new consent form for HEDS participation. This group will have outcome data abstracted from their medical records. c)   Vanguard Interval Cases are cirrhotic controls from the Phase 2 trial that developed HCC after completion of the Phase 2 trial but prior to the current study. This group will have outcome data abstracted from their medical records. d)   Vanguard Cases are HCC cases from the Phase 2 trial. This group will have outcome data abstracted from their medical records. Part 2: New Controls - The second part of this study is the new accrual of cirrhotic controls at the seven participating sites. These patients will be followed for a minimum of 24 months and have biospecimens collected every 6 months. Data will be collected every 6 months: ultrasound, AFP, liver function tests, complete blood counts, MELD scores and any changes in medical history, personal cancer history and family cancer history.

The Specific Aims of the HEDS study are: Aim 1:   (a) To determine the incidence rate and the performance of ultrasound, and the biomarkers, alpha-fetoprotein (AFP), AFP-L3%, and des-gamma carboxy-prothrombin (DCP), in detecting preclinical hepatocellular carcinoma (HCC). (b) To evaluate the performance of novel biomarkers for the detection of preclinical HCC. Aim 2:   To determine the cost-effectiveness of surveillance strategies for HCC. Aim 3:   To determine the performance of biomarkers in the prognosis of patients with HCC. Aim 4:   To establish a biorepository of longitudinally collected biospecimens from this cohort of cirrhotic patients. These biospecimens will form a reference set to be used for future EDRN biomarker validation research.
TBD

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.